

Award Number: W81XWH-10-1-0593

TITLE: Probiotic (VSL#3) for Gulf War Illness

PRINCIPAL INVESTIGATOR: Ashok Tuteja, M.D., M.P.H.

CONTRACTING ORGANIZATION: Western Institute For Biomedical Research  
Salt Lake City, UT 841148-0001

REPORT DATE: October 2013

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE</b> October 2013		<b>2. REPORT TYPE</b> Annual		<b>3. DATES COVERED</b> 8 September 2012 – 7 September 2013	
<b>4. TITLE AND SUBTITLE</b>  Probiotic (VSL#3) for Gulf War Illness				<b>5a. CONTRACT NUMBER</b>	
				<b>5b. GRANT NUMBER</b> W81XWH-10-1-0593	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b>  Ashok Tuteja, M.D.  <b>E-Mail:</b> ashok.tuteja@va.gov				<b>5d. PROJECT NUMBER</b>	
				<b>5e. TASK NUMBER</b>	
				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  Western Institute For Biomedical Research Salt Lake City, UT 841148-0001				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b>  The overall objective of the study is to determine whether probiotic VSL#3® will improve 1) intestinal symptoms of Irritable Bowel Syndrome and 2) non-intestinal symptoms (fatigue, joint pain, insomnia, general stiffness and headache) associated with IBS. All of these symptoms are part of the Gulf War illness. The project was approved by Human Research Protection Office, Department of Defense in August 2013. We received the drug shipment from the manufacturer of VSL#3 in September 2013. We are in contact with the Lawrence Berkeley Laboratories to arrange for shipment of stool samples and microflora analysis. We screened our first participant in September 2013.					
<b>15. SUBJECT TERMS</b> Irritable bowel syndrome, probiotic, Gulf War Illness, diarrhea					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>			<b>19b. TELEPHONE NUMBER</b> (include area code)
U	U	U	UU	9	USAMRMC

## Table of Contents

	<u>Page</u>
<b>Introduction.....</b>	<b>1</b>
Body.....	1
<b>Key Research Accomplishments.....</b>	<b>2</b>
<b>Reportable Outcomes.....</b>	<b>3</b>
<b>Conclusion.....</b>	<b>4</b>
<b>References.....</b>	<b>5</b>
<b>Appendices.....</b>	<b>6</b>

**Introduction:**

Gastroenteritis plays a major role in changing intestinal microflora. More than one third of Gulf War (GW) veterans report gastroenteritis during deployment and it is a risk factor for development of irritable bowel syndrome (IBS) after deployment. We also demonstrated that there is a strong association between IBS and extra-intestinal disorders (e.g. fatigue, joint pains, insomnia, generalized stiffness, and headache). This would suggest that IBS as well as extra-intestinal disorders in GW veterans have a unifying etiology. There is scientific evidence that probiotics by restoring normal gut flora improve symptoms of IBS. Probiotics have also been shown to improve arthritis and fatigue by changing fecal flora. This is the basis for our present protocol to study the effect of probiotics on GW illness.

**Body:**

During the last on year the following goals were accomplished:

- Study was approved by the University of Utah, Institutional Review Board in February 2013.
- Study was approved by the Human Research Protection Office at the United States Army Medical Research and Materiel command (USAMRMC), in August 2013.
- VSL Pharmaceuticals sent the drug shipment from Roma, Italy in September 2013. The drug was received at the VA pharmacy, Salt Lake City.
- First patient was enrolled in September 2013.
- Study co-investigator at Lawrence Berkeley Laboratories has been contacted for stool sample analysis.
- IRB approval for the study has been applied for, at the University of California, Berkeley.

**Key Research Accomplishments.....**

Nil.

**Reportable Outcomes.....**

Nil.

**Conclusion:**

This project has now been approved and is ready for enrollment.

The screening for this study has been started and two patients have been enrolled in the study.

**References.....**

Nil.

**Appendices.....**

Nil.